Transfection assays validated the tumor-suppressing effect of miR-23b-3p and modulated the expression of both ATG12 and GLS1 in sorafenib-resistant HepG2 cells, curtailing sorafenib resistance in HCC. Here, ATG12 is linked to hepatocellular carcinoma.